NCT04013919

Brief Summary

This is an observational, multicenter prospective study including up to 260 subjects with type 1 or type 2 diabetes who use insulin injections (either basal insulin only or multiple daily injections (MDI)) and CGM or SMBG to manage their diabetes. The study aims to generate the database needed for future development and verification of insulin-glucose modules of subjects with diabetes using insulin injections. During the study, subjects will continue their regular diabetes management using their regular glucose monitoring method (either CGM or SMBG), insulin injections and oral medication (as applicable). Subjects will be requested to document glucose levels and insulin delivery during basal only or basal/bolus insulin treatment. In addition, subjects will have their daily activities recorded (meals, physical activity etc) using electronic log (implemented on the CGM/FGM receiver, Dedicated App, Neura App and/or other logbooks). Data will be captured during regular daily life using Insulin Connected pens and daily diary application software, for a period of 1 month.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
260

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Sep 2019

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 8, 2019

Completed
2 days until next milestone

First Posted

Study publicly available on registry

July 10, 2019

Completed
2 months until next milestone

Study Start

First participant enrolled

September 20, 2019

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2020

Completed
Last Updated

December 26, 2019

Status Verified

December 1, 2019

Enrollment Period

6 months

First QC Date

July 8, 2019

Last Update Submit

December 22, 2019

Conditions

Outcome Measures

Primary Outcomes (1)

  • Glucose levels

    Characterise the insulin-glucose dynamics for insulin users

    1 month

Study Arms (2)

Type 1 Diabetes

Drug: Multiple Daily Injections of Insulin

Type 2 Diabetes

Drug: Multiple Daily Injections of InsulinDrug: Single insulin injections

Interventions

Basal/ Bolus insulin injections

Type 1 DiabetesType 2 Diabetes

Basal insulin injections only

Type 2 Diabetes

Eligibility Criteria

Age1 Year+
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Up to 260 subjects with diabetes mellitus will be recruited in the following distribution: up to 100 T1D and up to 160 T2D. All subjects will be using multiple daily injections of insulin or basal injections only and self-monitoring blood glucose or continuous glucose monitoring.

You may qualify if:

  • Documented T1D or T2D for at least 1 year prior to study enrolment
  • T1D: Subjects aged 1 year or older
  • T2D: Subjects aged 30 years or older
  • Subjects using basal-bolus MDI therapy or basal insulin only - basal insulin Lantus or Tregludec and any short acting insulin.
  • T2D: Insulin pumps will also be accepted.
  • T2D: BMI ≥ 25 kg/m2
  • Subjects willing to follow study instructions:
  • For SMBG users: measure capillary blood glucose at least 4 times a day and twice a week 7-point profile. Document blood glucose level, insulin delivery, meals and daily activities. Optional: wear blinded CGM.
  • For CGM users: Document insulin delivery, meals and daily activities. Optional:
  • Measure capillary blood glucose in addition.
  • Adult subjects or parents of pediatric subjects willing and able to sign a written informed consent form.

You may not qualify if:

  • An episode of diabetic keto-acidosis within the month prior to study entry and/or severe hypoglycemia resulting in seizure or loss of consciousness in the month prior to enrolment.
  • Concomitant diseases/ treatment that influence metabolic control (except diabetes treatment for T2) or any significant diseases /conditions including psychiatric disorders and substance abuse that in the opinion of the investigator is likely to affect the subject's ability to complete the study or compromise subject's safety
  • T2D: eGFR \< 60
  • Participation in any other interventional study
  • Female subject who is pregnant or planning to become pregnant within the planned study duration
  • T1D: Subject is in the "honeymoon" phase - i.e. less than 0.5 insulin units/kg per day.
  • Drug or alcohol abuse.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Scheider MC

Petah Tikva, 4952805, Israel

RECRUITING

MeSH Terms

Conditions

Diabetes Mellitus

Condition Hierarchy (Ancestors)

Glucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System Diseases

Central Study Contacts

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 8, 2019

First Posted

July 10, 2019

Study Start

September 20, 2019

Primary Completion

April 1, 2020

Study Completion

April 1, 2020

Last Updated

December 26, 2019

Record last verified: 2019-12

Data Sharing

IPD Sharing
Will not share

Locations